News & Events

2019

  • July 09, 2019Suven Life Sciences announces the delay in topline phase 2 study data of masupirdine (SUVN-502)View PDF
  • May 23, 2019Suven Life Sciences Ltd Announces the last patient last visit (LPLV) in their Phase 2 study of MasupView PDF
  • May 22, 2019Q4 and FY19 Schedule of conference call for InvestorsView PDF
  • April 22, 2019Suven completes the purchase of assets of Rising Pharmaceuticals through its joint venture partner,View PDF
  • April 13, 2019Suven receives court approval of “Stalking Horse” Agreement to buy the assets of Rising PharmaceuticView PDF
  • April 03, 2019Suven Life Sciences secures Product Patents in Israel, Japan, New Zealand and Sri LankaView PDF
  • March 29, 2019Suven Life Sciences secures Product Patents in Eurasia, Europe, South Korea and Sri LankaView PDF
  • March 08, 2019Suven announces the asset purchase agreement of Rising Pharmaceuticals through its joint venture parView PDF
  • February 05, 2019Suven Revenue up by 40.24%; PAT up by 40.27% for quarter ended December’ 2018View PDF
  • February 05, 2019Suven outcome of the Board MeetingView PDF
  • January 16, 2019Suven Life Sciences secures Product Patents in Australia and SingaporeView PDF
Archives